We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+6.1%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$289M
AUM Growth
-$53.5M
Cap. Flow
-$69.1M
Cap. Flow %
-23.93%
Top 10 Hldgs %
99.7%
Holding
12
New
–
Increased
8
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$242K
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$201K
3
ALKS icon
Alkermes
ALKS
+$136K
4
BIIB icon
Biogen
BIIB
+$135K
5
MCK icon
McKesson
MCK
+$120K

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$55.3M
2
UTHR icon
United Therapeutics
UTHR
+$12.2M
3
ANAB icon
AnaptysBio
ANAB
+$2.14M
4
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$456K

Sector Composition

Rank Sector Weight
1 Healthcare 97.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENTA icon
1
Enanta Pharmaceuticals
ENTA
$366M
$42.6M 14.73%
862,848
+4,037
+0.5% +$201K
UTHR icon
2
United Therapeutics
UTHR
$25.8B
$41.7M 14.44%
249,421
-73,116
-23% -$12.2M
TARO
3
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$40.4M 13.98%
547,639
-6,007
-1% -$456K
REGN icon
4
Regeneron Pharmaceuticals
REGN
$78.5B
$39.1M 13.54%
82,698
+498
+0.6% +$242K
BIIB icon
5
Biogen
BIIB
$30B
$38.8M 13.41%
138,518
+501
+0.4% +$135K
MCK icon
6
McKesson
MCK
$100B
$32.7M 11.32%
167,640
+657
+0.4% +$120K
ALKS icon
7
Alkermes
ALKS
$8.22B
$30.4M 10.52%
1,627,323
+6,648
+0.4% +$136K
SRGA
8
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$14.1M 4.87%
214,980
+866
+0.4% +$60.4K
IVC
9
DELISTED
Invacare Corporation
IVC
$7.28M 2.52%
908,236
+3,689
+0.4% +$34.4K
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$1.06M 0.37%
6,912
-357,362
-98% -$55.3M
ANAB icon
11
AnaptysBio
ANAB
$1.58B
$554K 0.19%
25,690
-84,758
-77% -$2.14M
NXTC icon
12
NextCure
NXTC
$16.8M
$306K 0.11%
2,550
+26
+1% +$3.77K

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Krensavage Asset Management held 12 positions worth $289M, down 16% from $342M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Krensavage Asset Management withdrew a net $69.1M in Q1 2021, reducing 4 holdings. Its largest reduction was Alexion Pharmaceuticals, cutting an estimated $55.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.

Against the trend, Krensavage Asset Management added an estimated $242K to Regeneron Pharmaceuticals.

  • Krensavage Asset Management added most to Regeneron Pharmaceuticals in Q1 2021, an estimated $242K increase.
  • Krensavage Asset Management's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $55.3M.
  • Krensavage Asset Management's ten largest holdings make up 100% of its $289M portfolio in Q1 2021.
  • Krensavage Asset Management opened 0 new positions and closed 0 in Q1 2021.
  • Krensavage Asset Management's portfolio value fell 16% quarter-over-quarter to $289M.

Based on Krensavage Asset Management's 13F filing for Q1 2021, filed 18 May 2021.